AUTL
Autolus Therapeutics Plc
NASDAQ · Healthcare · Biotechnology · GB
$1.59
−0.63%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.60
From 52W high−37.40%
Volume1.52M
Market cap$423.20M
P/E (TTM)—
P/S (TTM)3.6x
Div yield—
Key dataOct 19, 2026
Open
$1.60
From 52W high
−37.40%
Volume
1.52M
Market cap
$423.20M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.4x
P/E (TTM)
—
RSI (14)
33.7
MomentumView details →
1D Return
−0.63%
YTD Return
−21.11%
SummaryUpdated Jun 1, 2026
Autolus Therapeutics plc (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in London, United Kingdom. The company specializes in developing engineered T-cell therapies for cancer treatment, with its lead product AUCATZYL receiving FDA approval in November 2024 for treating relapsed or refractory acute lymphoblastic leukemia (ALL) in adults. Autolus has evolved from a pure research and development company to a commercial-stage biotechnology firm with its own manufacturing capabilities and an expanding pipeline of cell therapy candidates targeting both hematological cancers and autoimmune diseases.
Similar companies
Latest newsMore news →
Autolus Therapeutics announced the online publication of an abstract for longer-term follow-up data from its CARLYSLE trial, to be presented at the American College of Rheumatology Convergence 2026 meeting in Orlando, Florida, on November 6-11, 2026.14d agoThe U.S. Food and Drug Administration granted regenerative medicine advanced therapy (RMAT) designation to Autolus Therapeutics' obecabtagene autoleucel (obe-cel) for the treatment of systemic lupus erythematosus and lupus nephritis.41d agoAutolus Therapeutics reported preliminary second quarter 2026 net product revenue of approximately $45 million for AUCATZYL and a year-to-date gross margin of approximately 35%.78d ago